about
Impaired glucose and nutrient absorption in critical illness: is gastric emptying only a piece of the puzzle?Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelRelevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsTotal Phenytoin concentration is not well correlated with active free drug in critically-ill head trauma patients.Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensEvaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyMedications prescribed and occurrence of falls in general medicine inpatients.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsClinical Pharmacology Studies in Critically Ill Children.Can enteral antibiotics be used to treat pneumonia in the surgical intensive care unit? A clinical outcomes and cost comparison.Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.Predictive Performance of the Winter-Tozer and Derivative Equations for Estimating Free Phenytoin Concentration.Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill PatientsClinical review: Drug metabolism and nonrenal clearance in acute kidney injury.In Silico Testing of an Artificial-Intelligence-Based Artificial Pancreas Designed for Use in the Intensive Care Unit Setting.Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolismIntravenous to oral conversion of antihypertensives: a toolkit for guideline development.Antibiotic dosing in critically ill patients with acute kidney injury.Infectious diseases in the critically ill patients.Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia.Haloperidol dosing strategies in the treatment of delirium in the critically ill.Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.Approaches for dosage individualisation in critically ill patients.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.The effects of acute renal failure on drug metabolism.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.Pharmacokinetic considerations for drugs administered in the critically ill.Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation.A Review of Agents for Palliative Sedation/Continuous Deep Sedation: Pharmacology and Practical Applications.Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
P2860
Q33347977-AAF0B5E6-F2B8-4DF2-A78B-F1ECA25CE222Q33442897-61887A47-DF8E-4194-AEF8-91F4C4B2F008Q33574126-97A84766-0360-4660-8F82-2092A43840BCQ33763177-AD27CAD6-B136-4ED5-AB5D-603DFD71753AQ33828046-43C812DA-CB5B-4B1C-B634-822BDCD01B92Q34570886-704F5CAC-DA1C-462E-8F3E-FDBDB9C373A6Q35114591-6859E7CF-1118-4173-A6E1-EFE900D652F4Q35471575-2E6BC6CA-16CB-4281-B715-429F266FEB12Q36025902-A9962621-8C8B-4681-9C79-8E4AA7038377Q36120465-89E3ABF7-75BB-4D14-8B9D-A9D120C2CF3CQ36184433-81B98C57-EA69-4925-A0BD-DF93685189B9Q36288297-C2B1B8D4-FD00-49C5-A3C1-CC7659B99B48Q37225733-C86C336A-B264-4140-BE68-2BB9D0FCF79FQ37268459-E746D3A0-C7E4-4AA3-9B0C-8B0937ED2C67Q37336958-1B50D306-3F9E-44EB-AEA0-6A5C87892625Q37391407-ACAE226F-5EC4-4A27-8E23-ACC7A2E09086Q37461431-D7D95B24-1677-400A-861D-798EBF22BD6AQ37639909-BB5A2B72-2530-43C6-B2D7-DE128CA09AB3Q37643628-6662E2C5-19DF-4340-A5B9-8CDC582D03ACQ37645239-800BA05B-BF9F-42C3-B287-1386FE2F9663Q37779421-8A9A2615-C642-4D1E-8C34-B29F21043BA5Q37846092-73C44460-A169-4F56-B04D-C1C1CF40BBD9Q37867314-78F8DB5A-3627-4017-BB56-B49F2233EC75Q37949636-90EF3E54-EAA2-437F-A74F-F1E7EA20E8CAQ37950933-FFFFE6A7-E619-4DD9-95E1-CA20DA986563Q38040844-D62C6C8E-B12E-4EB1-B38C-431376387BEBQ38107537-CB03F641-CCA4-47E7-B213-0D069C58E47BQ38125209-74944665-9956-4E83-8F22-0C15F28193C2Q38140015-1C10A2A5-5AA0-46D4-B626-EF20FFF3D50EQ38145416-146810C8-4B3D-4C55-A10C-F9383B0F99D0Q38261172-FEE7354B-440C-4262-9988-CFAF93B24344Q38349536-9687F049-9CD6-487C-B60F-FBF28A1E704BQ38351793-773BAFB5-764C-4A6A-B71C-43A74A5FBDA8Q38374584-7788F553-5DB5-45A5-A9C2-13E2052E73F4Q38944443-BCA816F3-10B9-446F-9498-273A3687225EQ39033001-5E76F04A-20E7-44D5-949F-8AF722E48AE5Q39175922-42805488-1BA2-41B1-8471-39BBEC077C94Q39882067-AD1DE01A-86FB-4B92-AB1E-EA7F07B7E371Q40095692-0BC16292-0110-4F4E-94F5-793F883B7094Q40172540-8697539D-4FD9-4B0A-8D71-1B853DAC65C5
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Pharmacokinetic changes in critical illness.
@ast
Pharmacokinetic changes in critical illness.
@en
type
label
Pharmacokinetic changes in critical illness.
@ast
Pharmacokinetic changes in critical illness.
@en
prefLabel
Pharmacokinetic changes in critical illness.
@ast
Pharmacokinetic changes in critical illness.
@en
P2093
P1476
Pharmacokinetic changes in critical illness.
@en
P2093
Bradley A Boucher
G Christopher Wood
Joseph M Swanson
P304
255-71, vi
P356
10.1016/J.CCC.2006.02.011
P577
2006-04-01T00:00:00Z